A problem with insulin infusion pumps is the occurrence of tissue-site reactions, often due to insulin phenolic preservatives (IPPs) designed to prolong shelf life of the insulin inside the pump. These IPPs can often induce inflammation at the site of implantation.

In a recent study published in Biomedicines in August 2023, Drs. Marianna Sadagurski, Ulrike Klueh, and others hypothesized that mast cells (specialized immune cells) might be triggering the inflammatory response to IPPs. 

Two strains of mice were injected with an infusion pump containing phenols, creating inflammation.  The mast cell deficient strain of mice showed significantly less inflammation (e.g., less leukocytes, less edema) than controls, following a seven day infusion. This study demonstrates the therapeutic potential of targeting mast cells to reduce IPP-induced inflammation seen with infusion pumps, helping to potentially ensure prolonged insulin administration.

To learn more, visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452641/